CClinicalTrials.gg
CompletedNCT04296292LEOPARDUpdated Apr 6, 2022

The Lived Experience of Participants in an African Randomised Trial

An observational study in HIV and Cryptococcal Meningitis, sponsored by London School of Hygiene and Tropical Medicine. Completed at 3 sites in 3 countries. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-04-06.

Sponsored by London School of Hygiene and Tropical Medicine · Observational

Study type
Observational
Model
Other
Time perspective
Prospective
Enrollment
89
Ages
18 Years and older
Sex
All
01

Study summary

There has been no previous qualitative study conducted in a low-income setting which has aimed to explore the experience of individuals who enrol into a clinical trial for the management of a life-threatening illness. The investigators plan to collect data from trial participants, their next-of-kin, and researchers working on a multi-site randomised controlled trial for the treatment of HIV-associated cryptococcal meningitis.

Read the detailed description

Individuals recruited into clinical trials for life-threatening illnesses are particularly vulnerable and this is especially true in low-income settings. The decision to enrol may be influenced by existing inequalities, a poor healthcare infrastructure and the fear of death. Where patients are confused or unconscious the responsibility for this decision falls on the relatives. The objectives of this study are to learn from the experience of participants, relatives and researchers involved in a randomised controlled trial, AMBITION (ISRCTN 72509687), which is testing a novel treatment approach for HIV-associated cryptococcal meningitis and is recruiting participants from multiple sites across sub-Saharan Africa.

The investigators will collect data from trial participants and their relatives who provided consent on their behalf in Gaborone, Botswana; Kampala, Uganda and Harare, Zimbabwe. Interviews will follow a narrative approach and encourage the drawing of timelines. This will be supplemented by direct observation of the research process at each of the three recruiting hospitals. In addition, interviews will take place with researchers from the African and European institutions that form the partnership through which the trial is administered. Findings from the interviews will be prospectively fed back to the individual sites and Trial Management Group to improve the ongoing trial.

02

Conditions studied

  • HIV
  • Cryptococcal Meningitis
03

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Individuals enrolled onto the AMBITION trial and individuals who provided consent for them at the Gaborone, Kampala and Harare sites.

Researchers working on AMBITION at the Gaborone, Kampala, Harare trial sites and also in the UK or France.

Eligibility criteria

AMBITION Trial Participants

Inclusion Criteria:

  • Enrolled onto the AMBITION trial and has completed at least six weeks of follow-up
  • Not currently confused
  • Willing and able to consent to the study

Exclusion Criteria:

  • Nil

The next-of-kin of AMBITION Trial Participants

Inclusion Criteria:

  • Provided surrogate consent for an individual who was enrolled into the AMBITION trial
  • Willing and able to consent to the study

Exclusion Criteria:

  • Nil

AMBITION Researchers

Inclusion Criteria:

  • Currently or previously employed on the AMBITION trial
  • Willing and able to consent to the study

Exclusion Criteria:

  • Nil
04

Study design

Observational model
Other
Time perspective
Prospective
Enrollment
89 participants (actual)
Patient registry
No

Groups and cohorts

  • AMBITION Trial Participants

    Individuals who have been enrolled into the AMBITION trial

    Other: In-depth interviews

  • The next-of-kin of AMBITION Trial Participants

    Individuals who have provided consent for an AMBITION trial participant who had an abnormal mental status at baseline

    Other: In-depth interviews

  • AMBITION Researchers

    Individuals working on the AMBITION trial

    Other: In-depth interviews

Interventions

  • OtherIn-depth interviews

    In-depth interviews following a narrative line of enquiry and direct observation at each of the research sites

    Also known as: Direct observation

05

What researchers measure

Primary outcomes

  1. Experience and views of individuals involved in the AMBITION trial

    Interviews with AMBITION trial participants and their next-of-kin will be semi-structured and follow a loose interview guide that adopts a narrative approach to understand the experience of being diagnosed with HIV-associated cryptococcal meningitis, being approached and enrolling into the trial, undergoing invasive procedures, completing follow-up and then exiting the trial. Interviews will take place during and after the trial. Interviews with researchers will follow a thematic line of enquiry to understand how the trial can be improved for participants as well as how transnational research partnerships could be optimised for the benefit of researchers. Direct observations will help to contextualise the findings from the interviews by situating them within the clinical environment.

    Time frame: 18 months

06

Study locations

3 sites
  • Botswana Harvard AIDS Institute
    Gaborone, Botswana
  • Infectious Diseases Institute, Uganda
    Kampala, Uganda
  • University of Zimbabwe
    Harare, Zimbabwe
07

References and documents

Publications

  • Lawrence DS, Tsholo K, Ssali A, Mupambireyi Z, Hoddinott G, Nyirenda D, Meya DB, Ndhlovu C, Harrison TS, Jarvis JN, Seeley J. The Lived Experience Of Participants in an African RandomiseD trial (LEOPARD): protocol for an in-depth qualitative study within a multisite randomised controlled trial for HIV-associated cryptococcal meningitis. BMJ Open. 2021 Apr 5;11(4):e039191. doi: 10.1136/bmjopen-2020-039191. PubMed 33820784 ↗

Individual participant data

Plan to share: Undecided — Individual transcripts and field notes may be shared with other researchers upon request and agreement by investigators.

08

Registry details

Key details

Study ID
NCT04296292
Lead sponsor
London School of Hygiene and Tropical Medicine
Collaborators
Botswana Harvard AIDS Institute Partnership, Infectious Diseases Institute, Uganda, University of Zimbabwe
Responsible party
Sponsor
First posted
Mar 5, 2020
Start date
Feb 5, 2020
Primary completion
Jun 11, 2021
Completion
Jun 11, 2021
Last update
Apr 6, 2022

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion